Alzheimer's Disease (AD) and Parkinson's Disease (PD) represent the two most prevalent neurodegenerative disorders, affecting over 60 million people worldwide combined. While traditionally studied as distinct conditions with different clinical presentations—AD characterized by memory loss and cognitive decline, PD by motor dysfunction and Lewy body pathology—growing evidence reveals substantial molecular overlap between these diseases. Approximately 20-50% of PD patients develop dementia with clinical and pathological features of AD, and conversely, many AD patients exhibit Lewy body pathology at autopsy[@compta2019] [1]</a>. Understanding these shared mechanisms is critical for developing therapies that may benefit both conditions[@swarbrick2020]. [irwin2015 2015, *Neuropathologic correlates of Alzheimer](https://pubmed.ncbi.nlm.nih.gov/26617819/)
This page documents the convergent molecular pathways, genetic risk factors, pathological interactions, and therapeutic targets that underlie both AD and PD, providing a framework for understanding their co-occurrence and identifying shared therapeutic strategies. [sidransky2009 2009, *Multicenter analysis of glucocerebrosidase mutations in Parkinson](https://pubmed.ncbi.nlm.nih.gov/19843450/)
Alzheimer's Disease (AD) and Parkinson's Disease (PD) represent the two most prevalent neurodegenerative disorders, affecting over 60 million people worldwide combined. While traditionally studied as distinct conditions with different clinical presentations—AD characterized by memory loss and cognitive decline, PD by motor dysfunction and Lewy body pathology—growing evidence reveals substantial molecular overlap between these diseases. Approximately 20-50% of PD patients develop dementia with clinical and pathological features of AD, and conversely, many AD patients exhibit Lewy body pathology at autopsy[@compta2019] [1]</a>. Understanding these shared mechanisms is critical for developing therapies that may benefit both conditions[@swarbrick2020]. [irwin2015 2015, *Neuropathologic correlates of Alzheimer](https://pubmed.ncbi.nlm.nih.gov/26617819/)
This page documents the convergent molecular pathways, genetic risk factors, pathological interactions, and therapeutic targets that underlie both AD and PD, providing a framework for understanding their co-occurrence and identifying shared therapeutic strategies. [sidransky2009 2009, *Multicenter analysis of glucocerebrosidase mutations in Parkinson](https://pubmed.ncbi.nlm.nih.gov/19843450/)
Several genetic risk factors contribute to both AD and PD, revealing common molecular pathways of neurodegeneration[@lennon2023]. [schottlaender2015 2015, *Glucocerebrosidase activity influences the risk for Alzheimer](https://pubmed.ncbi.nlm.nih.gov/26315508/)
Heterozygous mutations in GBA1, encoding the lysosomal enzyme glucocerebrosidase, represent one of the strongest genetic risk factors for both PD and DLB. GBA mutations are found in 5-10% of PD patients and up to 20% of DLB patients, increasing risk 5-10 fold [2]</a>. The mechanism involves impaired lysosomal function leading to accumulation of glucocerebrosylceramide, which promotes alpha-synuclein aggregation and impairs autophagy. Interestingly, GBA mutations also increase risk of AD, particularly in individuals with concurrent Lewy body pathology [3]</a>. [tsuang2013 2013, *APOE modifies the association between in vivo Alzheimer neuropathology and c...](https://pubmed.ncbi.nlm.nih.gov/23547266/)
The APOE ε4 allele is the strongest genetic risk factor for late-onset AD, increasing risk 3-4 fold per allele. However, APOE ε4 also influences PD risk and progression. PD patients carrying APOE ε4 have earlier onset of motor symptoms, more rapid cognitive decline, and increased likelihood of developing dementia [4]</a>. APOE affects both conditions through effects on amyloid processing, neuroinflammation, lipid metabolism, and synaptic function. [di2020 2020, *The role of LRRK2 in neurodegeneration: contribution to Parkinson](https://pubmed.ncbi.nlm.nih.gov/33103757/)
LRRK2 mutations are a common cause of familial PD, but LRRK2 activity is also elevated in AD brains. LRRK2 regulates synaptic function, immune responses, and autophagy. Inhibition of LRRK2 has been proposed as a therapeutic strategy for both conditions 5</a>. Studies show LRRK2 expression is increased in AD [hippocampus and correlates with tau pathology. [hamilton2000 2000, *Lewy bodies in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/10885656/)
While SNCA mutations cause familial PD, alpha-synuclein pathology is present in most AD brains as well. Approximately 50-60% of AD patients have Lewy bodies at autopsy, and Lewy body density correlates with faster cognitive decline [6</a>. This suggests that alpha-synuclein aggregation represents a final common pathway that can be triggered by either AD or PD-specific mechanisms. [moors2021 2021, *Converging pathways of autophagy dysfunction in the aging and diseased brain...](https://pubmed.ncbi.nlm.nih.gov/33967052/)
Despite their different primary pathologies (amyloid/tau vs. alpha-synuclein), AD and PD share several downstream pathogenic mechanisms. [exner2012 2012, *Mitochondrial dysfunction in Parkinson](https://pubmed.ncbi.nlm.nih.gov/22735198/)
Both AD and PD involve profound defects in autophagy—the cellular process for degrading misfolded proteins and damaged organelles. In AD, impaired autophagic-lysosomal pathway leads to accumulation of Aβ and tau within autophagic vacuoles. In PD, defective mitophagy (mitochondrial autophagy) allows accumulation of dysfunctional mitochondria and promotes alpha-synuclein aggregation [7</a>. The shared involvement of lysosomal dysfunction through GBA mutations further links these pathways. [ulrich2017 2017, *Elucidating the role of TREM2 in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/28426957/)
Mitochondrial abnormalities are present in both conditions. In AD, amyloid-beta accumulates within mitochondria and inhibits electron transport chain complexes, particularly complex IV. In PD, mutations in PINK1, PRKN, and DJ-1 impair mitophagy, leading to accumulation of defective mitochondria. Both conditions show reduced complex I activity, elevated oxidative stress, and decreased ATP production [8</a>. This convergence suggests that mitochondrial protection may benefit both conditions. [hipp2019 2019, The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol](https://pubmed.ncbi.nlm.nih.gov/30920968/)
Chronic neuroinflammation is a hallmark of both AD and PD. Microglial activation is driven by amyloid plaques in AD and by alpha-synuclein aggregates in PD. Shared inflammatory pathways include: [bassil2021 2021, *Cross-seeding of misfolded proteins: implications for ALS and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/34244443/)
The protein quality control network—comprising molecular chaperones, the ubiquitin-proteasome system, and autophagy—is impaired in both diseases. In AD, ubiquitin-positive inclusions containing tau are a hallmark. In PD, Lewy bodies are ubiquitin-positive and also contain autophagy-related proteins. The shared accumulation of misfolded proteins suggests that enhancing proteostasis may benefit both conditions [10</a>. [compta2019 2019, *Combined Alzheimer](https://pubmed.ncbi.nlm.nih.gov/31722020/)
Growing evidence demonstrates direct molecular interactions between AD and PD pathologies. Amyloid-beta can promote alpha-synuclein aggregation through several mechanisms: [horimoto2020 2020, *Long-term survival with amyloid PET imaging in patients with Parkinson disea...](https://pubmed.ncbi.nlm.nih.gov/32934114/)
While tau pathology is characteristic of AD, 20-40% of PD patients also have tau-positive neurofibrillary tangles at autopsy. The presence of tau pathology in PD is associated with faster cognitive decline and earlier onset of dementia [12</a>. [Tau and alpha-synuclein may synergize: tau can promote α-synuclein aggregation, and α-synuclein can enhance tau phosphorylation. [chen2023 2023, *Plasma p-tau181 in Parkinson](https://pubmed.ncbi.nlm.nih.gov/37230795/)
Approximately 25-30% of PD patients have significant amyloid plaque pathology at autopsy. The presence of amyloid plaques in PD predicts more rapid cognitive decline and shorter survival [13</a>. This suggests that anti-amyloid therapies under development for AD may also benefit a subset of PD patients. [mckeith2017 2017, Diagnosis and management of dementia with Lewy bodies: consensus report. Ne...](https://pubmed.ncbi.nlm.nih.gov/28592453/)
| Biomarker | AD Changes | PD Changes | Clinical Utility | [aarsland2021 2021, *Parkinson](https://pubmed.ncbi.nlm.nih.gov/33641235/)
|-----------|------------|------------|------------------| [jellinger2013 2013, *More than the limbic system? Neuropathology of Parkinson](https://pubmed.ncbi.nlm.nih.gov/23161010/)
| CSF Aβ42 | ↓ Markedly | ↓ in PD with dementia | AD diagnosis, co-pathology detection | [swarbrick2020 2020, *Shared mechanisms of neurodegeneration in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/32785061/)
| CSF tau/p-tau | ↑ Prominently | ↑ in PD with dementia | AD progression, cognitive decline | [lennon2023 2023, Converging genetic risk for neurodegenerative diseases. Ann Neurol](https://pubmed.ncbi.nlm.nih.gov/36346152/)
| CSF α-synuclein | ↓ In LBD | ↓ In PD | Synuclein pathology detection | [chmielewska2020 2020, Lysosomal dysfunction in the pathogenesis of neurodegenerative diseases. In...](https://pubmed.ncbi.nlm.nih.gov/32967198/)
| CSF Neurogranin | ↑ Early | ↑ In PD dementia | Synaptic dysfunction in both |
| CSF NFL | ↑ Progressive | ↑ Progressive | Neurodegeneration rate |
| Blood GFAP | ↑ Early | ↑ In PD | Astrocyte activation |
| Blood p-tau181 | ↑ Early | ↑ In PD | AD pathology detection in PD |
The emergence of blood-based biomarkers, particularly p-tau181 and p-tau217, has enabled detection of AD pathology in living patients. Studies show elevated p-tau181 in PD patients, particularly those with cognitive impairment, suggesting shared tau mechanisms 14</a>.
PDD and DLB represent a clinical spectrum where parkinsonism and dementia co-occur. Both conditions feature:
Approximately 20-30% of AD patients meet criteria for AD with Lewy bodies, having both amyloid plaques/neurofibrillary tangles and Lewy bodies. These patients have:
Given the molecular convergence between AD and PD, several therapeutic strategies may benefit both conditions.
| Strategy | Mechanism | Development Status |
|----------|-----------|-------------------|
| GBA enzyme enhancement | Increase glucocerebrosidase activity | Preclinical |
| [TFEB activation | Stimulate lysosomal biogenesis | Phase 2 trials |
| Autophagy modulators | Enhance protein clearance | Phase 1/2 |
| Amphotericin B analogs | Restore GBA activity | Preclinical |
| Strategy | Mechanism | Development Status |
|----------|-----------|-------------------|
| CoQ10 | Electron transport chain support | Phase 3 failed in PD |
| MitoQ | Mitochondrial antioxidant | Phase 2 |
| NAD+ boosters | Support sirtuins, PARP repair | Phase 2 |
| Mitophagy inducers | Enhance PINK1/Parkin pathway | Preclinical |
| Strategy | Mechanism | Development Status |
|----------|-----------|-------------------|
| TREM2 agonists | Enhance microglial clearance | Phase 1/2 |
| NLRP3 inhibitors | Block inflammasome activation | Phase 1 |
| CSF1R antagonists | Reduce microglial proliferation | Phase 2 in ALS |
| Minocycline | Broad anti-inflammatory | Phase 3 negative |
| Strategy | Mechanism | Development Status |
|----------|-----------|-------------------|
| Complement inhibitors | Block C1q/C3 mediated pruning | Phase 1/2 |
| Sigma-2 receptor modulators | Displace oligomers from synapses | Phase 2 |
| Anti-Aβ immunotherapy | Reduce amyloid burden | Approved (lecanemab) |
| Neurotrophic factors | Support synaptic maintenance | Phase 1/2 |
| Feature | Alzheimer's Disease | Parkinson's Disease | Shared |
|---------|-------------------|---------------------|--------|
| Primary proteinopathy | Aβ, tau | α-synuclein | — |
| Typical onset | >65 years | >60 years | Late life |
| Core symptoms | Memory, cognition | Motor (tremor, bradykinesia) | Cognitive decline in both |
| Genetic risk (strongest) | APOE ε4 | LRRK2, GBA, SNCA | GBA, APOE, LRRK2 |
| Mitochondrial defect | Complex IV | Complex I | Multiple complexes |
| Autophagy defect | mTOR hyperactivation | Mitophagy failure | Lysosomal dysfunction |
| Neuroinflammation | Plaque-driven | Aggregate-driven | Microglial activation |
| CSF biomarker signature | ↓Aβ42, ↑tau | ↓α-syn | ↓Aβ42, ↑NFL in both |
Several clinical trials are targeting mechanisms shared between AD and PD:
| Trial ID | Phase | Intervention | Target | Disease | Status |
|----------|-------|--------------|--------|---------|--------|
| NCT05348785 | Phase II | BIIB122 (DNL151) | LRRK2 kinase | PD | Completed |
| NCT06033686 | Phase II | Lu AF87908 | Tau antibody | AD | Recruiting |
| NCT05477363 | Phase I | AJ201 | GBA modulator | PD | Recruiting |
| NCT05604469 | Phase I/II | ATN-034 | Alpha-synuclein antibody | PD | Active |
The shared biomarker profile between AD and PD enables cross-diagnostic approaches:
Understanding shared mechanisms has direct clinical implications: